Need any help? Call 01353 863279
Cambridge Nutritional Sciences Ltd
Eden Research Park
Henry Crabb Road
Littleport, Cambridgeshire
United Kingdom, CB6 1SE

TEL: 44 (0) 1353 863279
FAX: 44 (0) 1353 863330
Email: orders@camnutri.com
Web: www.camnutri.com

PLEASE NOTE THIS TEST IS BEING DISCONTINUED AT THE END OF APRIL

Technical Literature

1.Intended use
The H. pylori IgA test is a rapid ELISA method for the detection of IgA class antibodies to cellular components of Helicobacter pylori. It is intended as an aid to diagnosis of H. pylori  infections.  The components of the test are for in vitro diagnostic use only.

2. Explanation of the Test
H.pylori infection is a major causative factor in gastritis, gastric and duodenal ulcers and gastric cancer. The organism can be demonstrated by culture or by histological staining in 90% of affected patients. The distribution of the organism within the gut lining is patchy and can be missed during endoscopy.
Detection of serum antibodies to H.pylori is a reliable indicator of H.pylori infection and provides a rapid, simple and non-invasive method for diagnosing H.pylori infection. 
The kit uses an antigen preparation that has been partially purified to yield principally high molecular weight H.pylori membrane proteins.

3. Principle of the test
Diluted serum samples are incubated with partially purified H.pylori antigens immobilised on microtitre wells.  After washing away unbound serum components, rabbit anti-human IgA conjugated to horseradish peroxidase is added to the wells and this binds to surface-bound antibodies in the second incubation. Unbound conjugate is removed by washing, and a solution containing 3,3’,5,5’-tetramethylbenzidine (TMB) and enzyme substrate is added to trace specific antibody binding. Addition of stop solution terminates the reaction and provides the appropriate pH for colour development.  The optical densities of the standards, controls and samples are measured using a microplate reader at 450nm.  Optical density is directly proportional to antibody activity in the sample. 

Warren J R & Marshall B J Lancet 1983;I 1273-1275

Goodwin C S et al Int J Syst Bacteriol 1989, 39: 397 - 405

Rathbone B J et al Gut 1986;27, 635-641

Wyatt J L et al Scand J Gastroenterology 1989,24 (Sup 160):27-34

von Wuffen H & Grote H J Euro J Clinical Microbiol Infect Dis 1988, 1:559-565

Loffield R J L F, et al Lancet 1989,i:1182-1185

Johnson, B J et a Gut 1986, 27 1132-1137

Goodwin, C S Lancet 1988ii 1467-1469

Forman, D et al Int J Cancer 1990 46, 608-611

Seppala K M et al Scand J Gastroenterol 1992 27, 973-976

Nomura, A et al N Engl J Med 1991 325, 1132-1136

Kosunen, T U et al Lancet 1992, 339:893-895